This page contains a Flash digital edition of a book.
Imaging


imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606–10.


19. Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538–e548.


20. Hillengass J et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012;97(11):1757–60.


21. Merz M et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014;28(9):1902–8.


22. Ahn IE et al. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol 2015;33(1):115–23.


23. Hillengass J et al. The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken. Eur Radiol 2015;25(3):745–50.


24. Merz M et al. Dynamic contrast-enhanced magnetic resonance imaging for assessment of anti-angiogenic treatment effects in multiple myeloma. Clin Cancer Res 2015;21(1):106–12.


25. Hillengass J et al. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 2011;153(6):721–8.


multiple myeloma. Leukemia 2009;23:1545–56.


4. Pianko MJ et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clin Cancer Res 2014;20(23):5888–97.


5. Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012;159(5):499–513.


6. Regelink JC et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 2013;162(1): 50–61.


7. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989(249):256–64.


8. Schmaus MC, Neuhof D. [Radiotherapy for solitary plasmacytoma and multiple myeloma]. Radiologe 2014;54(6):551–5.


9. D'Anastasi M et al. [Radiological diagnostics of multiple myeloma]. Radiologe 2014;54(6):556–63.


10. Sauter A, Weisel K, Horger M. Imaging findings in relapsing multiple myeloma. Br J Haematol 2010;150(4):388.


11. Usmani SZ et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 2013;121(10):1819–23.


12. Kobe C et al. Assessment of tumor size reduction


improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol 2014;32(17):1776–81.


13. Wolf MB et al. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. Eur J Radiol 2014;83(7):1222–30.


14. Walker R et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25:1121–8.


15. Moulopoulos LA et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol 2012;87(9):861–4.


16. Waheed S et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 2013;98(1):71–8.


17. Hillengass J et al. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia 2014;28(1):174–8.


18. Hillengass J et al. Prognostic significance of focal lesions in whole-body magnetic resonance


26. Shah R et al. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases. Ann Hematol 2013;92(11):1553–7.


27. Kristinsson SY et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 2010;116(15):2651–5.


28. Terpos E et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;31(18):2347–57.


29. Andrulis M et al. Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. Eur J Radiol 2014;83:970–4.


30. Kyle RA et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7.


31. Kyle RA et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582–90.


32. Vogel MN et al. Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease. AJR Am J Roentgenol 2009;193:656–61.


www.hospitalpharmacyeurope.com


15


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32